High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer.

High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer.

Show other versions (1)

Estrogen receptor-positive (ER+) breast cancer intrinsically confers satisfactory clinical outcomes in response to endocrine therapy. However, a significant proportion of patients with ER+ breast cancer do not respond well to this treatment. Therefore, to evaluate the effects of endocrine therapy, t...

Full description

Bibliographic Details
Main Authors: Chotaro Onaga, Shoma Tamori, Izumi Matsuoka, Ayaka Ozaki, Hitomi Motomura, Yuka Nagashima, Tsugumichi Sato, Keiko Sato, Yuyun Xiong, Kazunori Sasaki, Shigeo Ohno, Kazunori Akimoto
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0268799

Internet

https://doi.org/10.1371/journal.pone.0268799

Similar Items